Julie Cullivan Sells 8,000 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) Director Julie Cullivan sold 8,000 shares of the company’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $27.32, for a total transaction of $218,560.00. Following the sale, the director directly owned 36,413 shares of the company’s stock, valued at $994,803.16. The trade was a 18.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Heartflow Price Performance

Shares of NASDAQ HTFL opened at $27.30 on Wednesday. Heartflow, Inc. has a 12-month low of $25.38 and a 12-month high of $41.22. The company has a market capitalization of $2.32 billion and a price-to-earnings ratio of -15.08. The firm’s 50 day simple moving average is $30.26.

Key Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Analyst upgrades and bullish price-target revisions remain on the tape (Wells Fargo started coverage with an “overweight”; Canaccord, JPMorgan and Stifel have raised targets toward ~$38–$40), supporting medium-term upside expectations.
• Neutral Sentiment: Several smaller institutional investors added positions in recent quarters — a modest vote of confidence but not large enough to offset other flows on its own.
• Negative Sentiment: CEO John C.M. Farquhar sold 22,562 shares at an average $27.46 (~$619.6k). Insider sales by the CEO can signal liquidity-taking and often weigh on sentiment. CEO Form 4
• Negative Sentiment: Director Julie Cullivan sold 8,000 shares at about $27.32 (~$218.6k), reducing her stake ~18%, which adds to negative insider-selling optics. Director Form 4
• Negative Sentiment: Reported large shareholder sell-off (headline noting ~$56.1M in stock sold) increases supply and likely pressured the share price. Major Shareholder Sale
• Negative Sentiment: Short interest surged in January to ~4.95M shares (up ~42% from mid‑January), representing ~5.8% of shares outstanding and ~5.9 days-to-cover — a material rise that can amplify downward moves as traders increase bearish positioning.

Hedge Funds Weigh In On Heartflow

Several large investors have recently made changes to their positions in HTFL. Wellington Management Group LLP purchased a new stake in shares of Heartflow during the third quarter worth about $164,263,000. Baillie Gifford & Co. purchased a new stake in Heartflow during the 3rd quarter valued at approximately $101,182,000. Schusterman Interests LLC purchased a new stake in Heartflow during the 3rd quarter valued at approximately $65,274,000. Vanguard Group Inc. raised its position in shares of Heartflow by 8.8% during the fourth quarter. Vanguard Group Inc. now owns 1,580,313 shares of the company’s stock valued at $46,066,000 after buying an additional 128,400 shares during the last quarter. Finally, Capital International Investors purchased a new position in shares of Heartflow in the third quarter worth $43,671,000.

Analyst Upgrades and Downgrades

HTFL has been the topic of several analyst reports. Canaccord Genuity Group lifted their target price on Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Stifel Nicolaus raised their price objective on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wells Fargo & Company began coverage on Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. raised their target price on shares of Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.